Aravive Investor Presentation Deck

Evidence of Batiraxcept to Maintain Response following Discontinuation of Chemotherapy from P1b PROC PROC 1B: batiraxcept monotherapy (15mg/kg) maintained complete response in 1 patient for 8 months and batiraxcept monotherapy (10mg/kg) maintained partial responses for 5 months in 2 patients following PAC and PLD and this is consistent with mechanism of action PAC = paclitaxel, PLD = pegylated liposomal doxorubicin 17

View entire presentation